SLB stock price rises on oil rally, dividend cutoff day draws focus

February 11, 2026
SLB stock price rises on oil rally, dividend cutoff day draws focus

NEW YORK, Feb 11, 2026, 14:12 EST — Regular session

  • SLB shares climbed 2.1%, reaching $51.38 in afternoon trading.
  • Oil jumped close to 2%, boosting oilfield services and other energy-related stocks.
  • SLB goes ex-dividend Wednesday, with its next payout scheduled for April 2.

SLB (SLB.N) shares climbed $1.06, or 2.1%, to $51.38 by 2:12 p.m. EST, having earlier hit $51.98. Halliburton (HAL.N) climbed 2.7%, while Baker Hughes (BKR.O) jumped 3.6%.

This shift is significant since oilfield service stocks usually act as a gauge for producers’ spending plans. When crude prices rise, investors typically expect increased drilling, maintenance, and offshore projects to receive funding—or at minimum, be protected.

SLB traded ex-dividend, so anyone purchasing shares from Wednesday on won’t get the upcoming quarterly payment. The dividend is set at $0.295 per share, with a payout date of April 2. 1

Crude prices climbed nearly 2% amid concerns over U.S.-Iran tensions, though a bigger-than-expected rise in U.S. crude inventories limited the upside, Reuters reported. “There are no signs, at least for now, of escalation,” PVM Oil Associates analyst Tamas Varga noted in a report, while UBS oil analyst Giovanni Staunovo pointed to Middle East tensions as a price support factor. 2

Oilfield services took a hit after Bloomberg News revealed Baker Hughes is considering a $1.5 billion sale of its Waygate Technologies unit. Baker Hughes didn’t respond when Reuters reached out for comment. 3

Investors are betting on SLB’s strong presence overseas, particularly in the Middle East. Just this month, the company secured a $1.5 billion, five-year contract with Kuwait Oil Company to handle the Mutriba field. This integrated development deal tasks SLB with the design, development, and production management of the project. 4

Offshore players haven’t been idle either. Transocean is set to acquire Valaris in a $5.8 billion all-stock agreement, according to Reuters. This move reflects a wider effort to grow amid customer cutbacks on new well projects and mounting pressure on suppliers to tighten pricing. 5

Support for SLB could quickly vanish if oil reverses this week’s rally. A softer stance on Iran or another spate of hefty inventory increases would challenge the buying driving the group higher.

Traders will be watching oil headlines closely while also tracking key calendar events that impact positioning. For SLB, the April 2 dividend payout is one to note.

Stock Market Today

  • Clarity Pharma Secures Supply Deal to Boost Prostate Cancer Drug Commercialisation
    March 24, 2026, 10:50 PM EDT. Clarity Pharmaceuticals (ASX: CU6) has signed a large-scale supply agreement with Theragenics to manufacture copper-64, a key isotope for its prostate cancer drug 64Cu-SAR-bisPSMA. Theragenics' cyclotron facility near Atlanta can produce up to 100Ci of Cu-64 daily per cyclotron, supporting about 2,000 patient doses. The deal prepares Clarity for commercial launch pending FDA approval after Phase III trials, including AMPLIFY 1 and CLARIFY 2. The copper-64 isotope's 12.7-hour half-life and the drug's 48-hour shelf life improve logistics. The Phase III trial exceeded recruitment targets, and recent data showed 64Cu-SAR-bisPSMA outperformed standard imaging in lesion detection. Despite a $55.6 million half-year loss and no revenue, Clarity's streamlined operations focus on commercial readiness for oncology applications.